Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Expert Opinion on Drug Safety|April 17, 2024
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance studyHui Yang, Zhexin Ding, Zhuoling An, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 23, 2019
Targeted amino acid and related amines analysis based on iTRAQ®-LC-MS/MS for discovering potential hepatotoxicity biomarkersZhuoling An, Ting Hu, Yali Lv, et al.
Frontiers in Oncology|September 29, 2022
Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance studyYizhang Hu, Wenchao Lu, Borui Tang, et al.
Breast (Edinburgh, Scotland)|February 26, 2022
Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trialsYi Zhang, Zhuo Ma, Ximu Sun, et al.
Frontiers in Pharmacology|January 24, 2022
Integration Analysis of Pharmacokinetics and Metabolomics to Predict Metabolic Phenotype and Drug Exposure of RemdesivirPing Du, Guoyong Wang, Ting Hu, et al.
Frontiers in Immunology|February 28, 2022
Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of AnlotinibPing Du, Lingling Xuan, Ting Hu, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 23, 2019
A sensitive and efficient method for simultaneous profiling of bile acids and fatty acids by UPLC-MS/MSTing Hu, Zhuoling An, Chen Shi, et al.
The Analyst|August 6, 2019
A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic studyPing Du, Yin Guan, Zhuoling An, et al.
Patient Preference and Adherence|March 24, 2025
Implementation of Guideline-Based Use of Proton Pump Inhibitors for Perioperative Stress Ulcer Prophylaxis: A Pre-Post Study Guided by CFIR-ERICXinrui Wang, Ying Liu, Yi Zhang, et al.
Frontiers in Pharmacology|August 9, 2023
Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting systemYing Zhang, Li Ran, Yongchao Liang, et al.
Pageof 11